FERRERI, ANDRES JOSE MARIA
FERRERI, ANDRES JOSE MARIA
Facoltà di Medicina e Chirurgia
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial
2021-01-01 Ferreri, A. J. M.; Cattaneo, C.; Lleshi, A.; Verga, L.; Allione, B.; Facchetti, F.; Ponzoni, M.; Foppoli, M.; Ferrari, D.; Rigacci, L.; Pecciarini, L.; Donadoni, G.; Fumagalli, L.; Sassone, M.; Calimeri, T.; Rossi, G.; Spina, M.; Re, A.
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
2020-01-01 Carlo-Stella, C.; Delarue, R.; Scarfo', L.; Barde, P. J.; Nair, A.; Locatelli, S. L.; Morello, L.; Magagnoli, M.; Vakkalanka, S.; Viswanadha, S.; Ferreri, A. J. M.
A multicenter study of treatment of primary CNS lymphoma
2002-01-01 Ferreri, Ajm; Reni, M; Pasini, F; Calderoni, A; Tirelli, U; Pivnik, A; Aondio, Gm; Ferrarese, F; Gomez, H; Ponzoni, Maurilio; Borisch, B; Berger, F; Chassagne, C; Iuzzolino, P; Carbone, A; Weis, J; Pedrinis, E; Motta, T; Jouvet, A; Barbui, T; Cavalli, F; Blay, Jy
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE
2010-01-01 Licata, G; Foppoli, M; Corazzelli, G; Zucca, E; Stelitano, C; Zaja, F; Fava, S; Paolini, R; Franzin, A; Politi, L; Ponzoni, Maurilio; Caligaris Cappio, F; Reni, M; Ferreri, A.
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma
2022-01-01 Steffanoni, S.; Calimeri, T.; Anzalone, N.; Mastaglio, S.; Bernardi, M.; Ferreri, A. J. M.
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial
2021-01-01 Fox, C. P.; Ali, A. S.; Mcilroy, G.; Thust, S.; Martinez-Calle, N.; Jackson, A. E.; Hopkins, L. M.; Thomas, C. M.; Kassam, S.; Wright, J.; Chaganti, S.; Smith, J.; Chau, I.; Culligan, D.; Linton, K. M.; Collins, G. P.; Ferreri, A. J. M.; Lewis, D.; Davies, A. J.; Johnson, R.; Auer, D. P.; Cwynarski, K.
A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL)
2011-01-01 Govi, S; Dolcetti, R; Ponzoni, Maurilio; Pasini, E; Mappa, S; Doglioni, C; Bertoni, F; Zaja, F; Montalban, C; Stelitano, C; Cabrera, Me; Cavalli, F; Zucca, E; Ferreri, Aj
A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27)
2010-01-01 Govi, S; Dolcetti, R; Ponzoni, M; Pasini, E; Doglioni, C; Bertoni, F; Cabrera, Me; Stelitano, C; Zaja, F; Sanz, Cm; Cavalli, F; Zucca, E; Ferreri, A
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma
2013-01-01 Ponzoni, Maurilio; Govi, S; Licata, G; Mappa, S; Giordano Resti, A; Politi, Ls; Spagnuolo, L; Di Cairano, E; Doglioni, Claudio; Ferreri, Aj
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
2020-01-01 Xu-Monette, Z. Y.; Zhang, H.; Zhu, F.; Tzankov, A.; Bhagat, G.; Visco, C.; Dybkaer, K.; Chiu, A.; Tam, W.; Zu, Y.; Hsi, E. D.; You, H.; Huh, J.; Ponzoni, M.; Ferreri, A. J. M.; Moller, M. B.; Parsons, B. M.; Van Krieken, J. H.; Piris, M. A.; Winter, J. N.; Hagemeister, F. B.; Shahbaba, B.; De Dios, I.; Zhang, H.; Li, Y.; Xu, B.; Albitar, M.; Young, K. H.
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme
2000-01-01 Reni, M; Cozzarini, C; Ferreri, Ajm; Ceresoli, Gl; Galli, L; Bianchi, A; Villa, E
A retrospective series of upfront therapy in primary brain lymphomas
2000-01-01 Reni, M; Ferreri, Ajm; Dell’Oro, S; Vavassori, V; Merlotti, A; Tordiglione, M; Villa, E.
A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type
2008-01-01 Ferreri, Ajm; Dognini, Gp; Crocchiolo, R; Govi, S; Licata, G; Ponzoni, Maurilio; Resti, Ag; Politi, Ls; Rosso, A; Villa, E.
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals
2007-01-01 Ponzoni, Maurilio; Kwee, I; Mazzucchelli, L; Ferreri, Ajm; Zucca, E; Doglioni, C; Cavalli, F; Bertoni, F.
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas
2004-01-01 Ferreri, Ajm; Dell'Oro, S; Capello, D; Ponzoni, Maurilio; Iuzzolino, P; Rossi, D; Pasini, F; Ambrosetti, A; Orvieto, E; Ferrarese, F; Arrigoni, G; Foppoli, M; Reni, M; Gaidano, G.
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS
2009-01-01 Crocchiolo, R; Gov, S; Ventre, Mb; Assanelli, A; Dognini, G; Ghia, P; Ciceri, Fabio; Ferreri, Ajm
Activity of rituximab in extranodal marginal zone lymphomas (MALT-type).
2001-01-01 Conconi, A; Thieblemont, C; Martinelli, G; Ferreri, Ajm; Devizzi, L; Peccatori, F; Ponzoni, Maurilio; Filipazzi, V; Dietrich, Py; Gianni, Ma; Cavalli, F; Zucca, E.
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens
2002-01-01 Reni, M; Panucci, Mg; Balzano, G; Ferreri, Aj; Passoni, P; Zerbi, A; Cordio, S; Ceresoli, Gl; Dell'Oro, S; Staudacher, C; Di Carlo, V; Villa, E.
Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents
2021-01-01 Deng, M.; Xu-Monette, Z. Y.; Pham, L. V.; Wang, X.; Tzankov, A.; Fang, X.; Zhu, F.; Visco, C.; Bhagat, G.; Dybkaer, K.; Chiu, A.; Tam, W.; Zu, Y.; Hsi, E. D.; You, H.; Huh, J.; Ponzoni, M.; Ferreri, A. J. M.; Moller, M. B.; Parsons, B. M.; Hagemeister, F.; van Krieken, J. H.; Piris, M. A.; Winter, J. N.; Li, Y.; Xu, B.; Liu, P.; Young, K. H.
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma
2017-01-01 Wang, J.; Xu-Monette, Z. Y.; Jabbar, K. J.; Shen, Q.; Manyam, G. C.; Tzankov, A.; Visco, C.; Wang, J.; Montes-Moreno, S.; Dybkaer, K.; Tam, W.; Bhagat, G.; Hsi, E. D.; van Krieken, J. H.; Ponzoni, M.; Ferreri, A. J. M.; Wang, S.; Moller, M. B.; Piris, M. A.; Medeiros, L. J.; Li, Y.; Pham, L. V.; Young, K. H.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial | 1-gen-2021 | Ferreri, A. J. M.; Cattaneo, C.; Lleshi, A.; Verga, L.; Allione, B.; Facchetti, F.; Ponzoni, M.; Foppoli, M.; Ferrari, D.; Rigacci, L.; Pecciarini, L.; Donadoni, G.; Fumagalli, L.; Sassone, M.; Calimeri, T.; Rossi, G.; Spina, M.; Re, A. | |
| A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study | 1-gen-2020 | Carlo-Stella, C.; Delarue, R.; Scarfo', L.; Barde, P. J.; Nair, A.; Locatelli, S. L.; Morello, L.; Magagnoli, M.; Vakkalanka, S.; Viswanadha, S.; Ferreri, A. J. M. | |
| A multicenter study of treatment of primary CNS lymphoma | 1-gen-2002 | Ferreri, Ajm; Reni, M; Pasini, F; Calderoni, A; Tirelli, U; Pivnik, A; Aondio, Gm; Ferrarese, F; Gomez, H; Ponzoni, Maurilio; Borisch, B; Berger, F; Chassagne, C; Iuzzolino, P; Carbone, A; Weis, J; Pedrinis, E; Motta, T; Jouvet, A; Barbui, T; Cavalli, F; Blay, Jy | |
| A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE | 1-gen-2010 | Licata, G; Foppoli, M; Corazzelli, G; Zucca, E; Stelitano, C; Zaja, F; Fava, S; Paolini, R; Franzin, A; Politi, L; Ponzoni, Maurilio; Caligaris Cappio, F; Reni, M; Ferreri, A. | |
| A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma | 1-gen-2022 | Steffanoni, S.; Calimeri, T.; Anzalone, N.; Mastaglio, S.; Bernardi, M.; Ferreri, A. J. M. | |
| A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial | 1-gen-2021 | Fox, C. P.; Ali, A. S.; Mcilroy, G.; Thust, S.; Martinez-Calle, N.; Jackson, A. E.; Hopkins, L. M.; Thomas, C. M.; Kassam, S.; Wright, J.; Chaganti, S.; Smith, J.; Chau, I.; Culligan, D.; Linton, K. M.; Collins, G. P.; Ferreri, A. J. M.; Lewis, D.; Davies, A. J.; Johnson, R.; Auer, D. P.; Cwynarski, K. | |
| A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL) | 1-gen-2011 | Govi, S; Dolcetti, R; Ponzoni, Maurilio; Pasini, E; Mappa, S; Doglioni, C; Bertoni, F; Zaja, F; Montalban, C; Stelitano, C; Cabrera, Me; Cavalli, F; Zucca, E; Ferreri, Aj | |
| A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27) | 1-gen-2010 | Govi, S; Dolcetti, R; Ponzoni, M; Pasini, E; Doglioni, C; Bertoni, F; Cabrera, Me; Stelitano, C; Zaja, F; Sanz, Cm; Cavalli, F; Zucca, E; Ferreri, A | |
| A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma | 1-gen-2013 | Ponzoni, Maurilio; Govi, S; Licata, G; Mappa, S; Giordano Resti, A; Politi, Ls; Spagnuolo, L; Di Cairano, E; Doglioni, Claudio; Ferreri, Aj | |
| A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL | 1-gen-2020 | Xu-Monette, Z. Y.; Zhang, H.; Zhu, F.; Tzankov, A.; Bhagat, G.; Visco, C.; Dybkaer, K.; Chiu, A.; Tam, W.; Zu, Y.; Hsi, E. D.; You, H.; Huh, J.; Ponzoni, M.; Ferreri, A. J. M.; Moller, M. B.; Parsons, B. M.; Van Krieken, J. H.; Piris, M. A.; Winter, J. N.; Hagemeister, F. B.; Shahbaba, B.; De Dios, I.; Zhang, H.; Li, Y.; Xu, B.; Albitar, M.; Young, K. H. | |
| A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme | 1-gen-2000 | Reni, M; Cozzarini, C; Ferreri, Ajm; Ceresoli, Gl; Galli, L; Bianchi, A; Villa, E | |
| A retrospective series of upfront therapy in primary brain lymphomas | 1-gen-2000 | Reni, M; Ferreri, Ajm; Dell’Oro, S; Vavassori, V; Merlotti, A; Tordiglione, M; Villa, E. | |
| A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type | 1-gen-2008 | Ferreri, Ajm; Dognini, Gp; Crocchiolo, R; Govi, S; Licata, G; Ponzoni, Maurilio; Resti, Ag; Politi, Ls; Rosso, A; Villa, E. | |
| A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals | 1-gen-2007 | Ponzoni, Maurilio; Kwee, I; Mazzucchelli, L; Ferreri, Ajm; Zucca, E; Doglioni, C; Cavalli, F; Bertoni, F. | |
| Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas | 1-gen-2004 | Ferreri, Ajm; Dell'Oro, S; Capello, D; Ponzoni, Maurilio; Iuzzolino, P; Rossi, D; Pasini, F; Ambrosetti, A; Orvieto, E; Ferrarese, F; Arrigoni, G; Foppoli, M; Reni, M; Gaidano, G. | |
| ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS | 1-gen-2009 | Crocchiolo, R; Gov, S; Ventre, Mb; Assanelli, A; Dognini, G; Ghia, P; Ciceri, Fabio; Ferreri, Ajm | |
| Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). | 1-gen-2001 | Conconi, A; Thieblemont, C; Martinelli, G; Ferreri, Ajm; Devizzi, L; Peccatori, F; Ponzoni, Maurilio; Filipazzi, V; Dietrich, Py; Gianni, Ma; Cavalli, F; Zucca, E. | |
| Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens | 1-gen-2002 | Reni, M; Panucci, Mg; Balzano, G; Ferreri, Aj; Passoni, P; Zerbi, A; Cordio, S; Ceresoli, Gl; Dell'Oro, S; Staudacher, C; Di Carlo, V; Villa, E. | |
| Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents | 1-gen-2021 | Deng, M.; Xu-Monette, Z. Y.; Pham, L. V.; Wang, X.; Tzankov, A.; Fang, X.; Zhu, F.; Visco, C.; Bhagat, G.; Dybkaer, K.; Chiu, A.; Tam, W.; Zu, Y.; Hsi, E. D.; You, H.; Huh, J.; Ponzoni, M.; Ferreri, A. J. M.; Moller, M. B.; Parsons, B. M.; Hagemeister, F.; van Krieken, J. H.; Piris, M. A.; Winter, J. N.; Li, Y.; Xu, B.; Liu, P.; Young, K. H. | |
| AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma | 1-gen-2017 | Wang, J.; Xu-Monette, Z. Y.; Jabbar, K. J.; Shen, Q.; Manyam, G. C.; Tzankov, A.; Visco, C.; Wang, J.; Montes-Moreno, S.; Dybkaer, K.; Tam, W.; Bhagat, G.; Hsi, E. D.; van Krieken, J. H.; Ponzoni, M.; Ferreri, A. J. M.; Wang, S.; Moller, M. B.; Piris, M. A.; Medeiros, L. J.; Li, Y.; Pham, L. V.; Young, K. H. |